{"url":"https://lda.senate.gov/api/v1/filings/a18c8f36-e6c2-469d-a3cb-d0807f7b9e10/","filing_uuid":"a18c8f36-e6c2-469d-a3cb-d0807f7b9e10","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2009,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/a18c8f36-e6c2-469d-a3cb-d0807f7b9e10/print/","filing_document_content_type":"text/html","income":null,"expenses":"100000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Nigel Lilley, Director of Strategic Development","dt_posted":"2009-07-10T14:45:51-04:00","termination_date":null,"registrant_country":"Canada","registrant_ppb_country":null,"registrant_address_1":"155 INNOVATION DRIVE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WINNIPEG","registrant_state":"MB","registrant_zip":null,"registrant":{"id":305657,"url":"https://lda.senate.gov/api/v1/registrants/305657/","house_registrant_id":38134,"name":"CANGENE CORPORATION","description":null,"address_1":"155 INNOVATION DRIVE","address_2":null,"address_3":"WINNIPEG","address_4":"MB R3T 5","city":"WINNIPEG","state":"MB","state_display":"MB","zip":"R3T 5-Y3","country":"CA","country_display":"Canada","ppb_country":"CA","ppb_country_display":"Canada","contact_name":"JANET RACZ","contact_telephone":"+1 204-275-4596","dt_updated":"2022-04-06T16:07:29.710707-04:00"},"client":{"id":181599,"url":"https://lda.senate.gov/api/v1/clients/181599/","client_id":12,"name":"CANGENE CORPORATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":null,"state_display":null,"country":"CA","country_display":"Canada","ppb_state":null,"ppb_state_display":null,"ppb_country":"CA","ppb_country_display":"Canada","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"H.R. 1 & S. 336: matters related to biomedical vaccines, biomedical therapeutics, biodefense and pandemic preparedness.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":41751,"prefix":null,"prefix_display":null,"first_name":"NIGEL","nickname":null,"middle_name":null,"last_name":"LILLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}